Table 1.
Patient characteristics
| Characteristic | ||
|---|---|---|
| No. pts | 30 | |
| Median age (range) | 69 | (47–80) |
| Median ng/ml pretherapy PSA (range) | 110 (1.2–3,716.9) | |
| No. performance status (%): | ||
| 0 | 8 | (27) |
| 1 | 15 | (50) |
| 2 | 7 | (23) |
| No. prostatectomy (%): | ||
| Yes | 11 | (37) |
| No | 19 | (63) |
| No. bone pain (%): | ||
| Yes | 21 | (70) |
| No | 9 | (30) |
| No. Gleason score (%): | ||
| 6 | 2 | (7) |
| 7 | 9 | (30) |
| 8–10 | 18 | (60) |
| Unknown | 1 | (3) |
| No. race (%): | ||
| White | 21 | (70) |
| Black | 9 | (30) |
| No. mos pretherapy PSA doubling time (%): | ||
| 1 or Less | 8 | (26) |
| 1–2 Mos | 13 | (44) |
| 2–4 Mos | 7 | (23) |
| Greater than 4 | 2 | (7) |
| No. prior adjuvant/neoadjuvant chemotherapy (%): | ||
| Docetaxel | 2 | (7) |
| None | 0 | (93) |
| No. progression/metastasis type (%): | ||
| Measurable disease | 9 | (30) |
| Bone metastasis progression | 18 | (60) |
| PSA progression | 22 | (73) |